Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib maintenance in stage III EGFR+ NSCLC
NCT04951635Phase 3Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Almonertinib Arm with Placebo Arm (2 arms). Primary endpoint: Progression-Free Survival up to 3 years. Started Mar 2021; status: recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04951635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951635.